Remove Communication Remove Drug Development Remove Pharmaceutical Companies
article thumbnail

The Benefits of Integrated CDMO Services: Streamlining Drug Development and Manufacturing

Drug Patent Watch

This shift has led to the emergence of integrated contract development and manufacturing organizations (CDMOs), which provide end-to-end support for drug developers. The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48 from 2023 to 2030.

article thumbnail

CDMO Selection: The Ultimate Checklist

Drug Patent Watch

This growth has created a competitive landscape where pharmaceutical companies must carefully evaluate and select the right CDMO partner to ensure the success of their projects. Your Drugs Development Stage The stage of your drug development is a critical factor in selecting a CDMO.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Deep Dive: Communications and Commercialisation

pharmaphorum

The COVID-19 pandemic kickstarted a period of profound change in how the pharmaceutical industry approaches both communications and commercialisation. The pharma company’s senior vice president for major markets talks about the continued evolution of the industry’s approach to communications and commercialisation.

article thumbnail

How using AI in clinical trials accelerates drug development

Pharmaceutical Technology

The need for new medical treatments and drugs has never been greater. But before pharmaceutical companies can go to market with a breakthrough drug, they need to ensure safety and efficacy through clinical trials. Even reaching the clinical trial phase offers no guarantees, as only 12% of such drugs receive U.S.

article thumbnail

Patient Engagement in Pharma – Why and How?

Viseven

In an era where medicine is rapidly becoming more personalized, why do pharmaceutical companies still struggle to effectively engage with the very individuals they aim to serve? This change is further driven by major regulatory bodies emphasizing Patient-Focused Drug Development (PFDD). Let’s break them down below.

article thumbnail

Effective Drug Patent Prosecution Strategies: Securing Your Pharmaceutical Innovations

Drug Patent Watch

This exclusivity is the lifeblood of pharmaceutical innovation, allowing companies to recoup their massive R&D investments and incentivizing further research. According to a 2021 study by the Tufts Center for the Study of Drug Development, the average cost to develop a new drug is a staggering $2.6

article thumbnail

Alexion’s Camilla Harder Hartvig on making the impossible possible in rare disease

pharmaphorum

“There’s a lot that drug development for more common diseases could learn from rare disease R&D”. I think there’s a lot that drug development for more common diseases could learn from rare disease R&D.”. We have to be innovative to get around those challenges. Rare diseases during COVID.

Hospitals 111